GeoVax Labs Q2 2024: Financing Activities Highlighted
Ticker: GOVX · Form: 10-Q · Filed: Aug 6, 2024 · CIK: 832489
Sentiment: neutral
Topics: 10-Q, financing, subsequent-event
TL;DR
GeoVax Labs Q2 2024 10-Q shows recent financing deals in July 2024, including warrant and direct offerings.
AI Summary
GeoVax Labs, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial performance and business activities. Key events disclosed include several financing activities in July 2024, such as a prefunded warrants offering on July 18, 2024, and a registered direct offering on July 12, 2024.
Why It Matters
This filing provides insight into GeoVax Labs' financial health and strategic moves, particularly its recent financing efforts which could impact future operations and stock dilution.
Risk Assessment
Risk Level: medium — The company's reliance on financing activities and potential for stock dilution presents a medium risk.
Key Numbers
- Q2 2024 — Reporting Period (Covers the second quarter of 2024.)
- 20240630 — Period End Date (The end date for the financial reporting period.)
- 20240806 — Filing Date (The date the 10-Q was officially filed with the SEC.)
Key Players & Entities
- GeoVax Labs, Inc. (company) — Filer
- 20240630 (date) — Reporting Period End Date
- 20240806 (date) — Filing Date
- July 18, 2024 (date) — Prefunded Warrants Offering Date
- July 12, 2024 (date) — Registered Direct Offering Date
FAQ
What were the key financing activities undertaken by GeoVax Labs in July 2024?
GeoVax Labs engaged in several financing activities in July 2024, including a prefunded warrants offering on July 18, 2024, and a registered direct offering on July 12, 2024.
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ending June 30, 2024.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted to the SEC on August 6, 2024.
What is GeoVax Labs' Standard Industrial Classification code?
GeoVax Labs' Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Has GeoVax Labs undergone any previous name changes?
Yes, GeoVax Labs has had previous names including DAUPHIN TECHNOLOGY INC (name change on 19940826) and SUCCESSO INC (name change on 19910410).
Filing Stats: 4,460 words · 18 min read · ~15 pages · Grade level 16 · Accepted 2024-08-06 16:00:33
Key Financial Figures
- $0.001 — ange on which Registered Common Stock $0.001 par value GOVX The Nasdaq Capital M
Filing Documents
- govx20240630_10q.htm (10-Q) — 601KB
- ex_706759.htm (EX-10.1) — 289KB
- ex_706760.htm (EX-10.2) — 464KB
- ex_706761.htm (EX-31.1) — 12KB
- ex_706762.htm (EX-31.2) — 11KB
- ex_706763.htm (EX-32.1) — 4KB
- ex_706764.htm (EX-32.2) — 4KB
- a01.jpg (GRAPHIC) — 17KB
- 0001437749-24-024867.txt ( ) — 3898KB
- govx-20240630.xsd (EX-101.SCH) — 33KB
- govx-20240630_def.xml (EX-101.DEF) — 223KB
- govx-20240630_lab.xml (EX-101.LAB) — 188KB
- govx-20240630_pre.xml (EX-101.PRE) — 239KB
- govx-20240630_cal.xml (EX-101.CAL) — 26KB
- govx20240630_10q_htm.xml (XML) — 280KB
– FINANCIAL INFORMATION
PART I – FINANCIAL INFORMATION Item 1 Condensed Consolidated Financial Statements: Condensed Consolidated Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023 1 Condensed Consolidated Statements of Operations for the three-month and six-month periods ended June 30, 2024 and 2023 (unaudited) 2 Condensed Consolidated Statements of Changes in Stockholders' Equity for the three-month and six-month periods ended June 30, 2024 and 2023 (unaudited) 3 Condensed Consolidated Statements of Cash Flows for the six-month periods ended June 30, 2024 and 2023 (unaudited) 4 Notes to Condensed Consolidated Financial Statements (unaudited) 5 Item 2
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 9 Item 3
Quantitative and Qualitative Disclosures about Market Risk
Quantitative and Qualitative Disclosures about Market Risk 15 Item 4
Controls and Procedures
Controls and Procedures 15
– OTHER INFORMATION
PART II – OTHER INFORMATION Item 1
Legal Proceedings
Legal Proceedings 16 Item 1A
Risk Factors
Risk Factors 16 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 16 Item 3 Defaults Upon Senior Securities 16 Item 4 Mine Safety Disclosures 16 Item 5 Other Information 16 Item 6 Exhibits 17
-- FINANCIAL INFORMATION
Part I -- FINANCIAL INFORMATION Item 1
Financial Statements
Financial Statements GEOVAX LABS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2024 2023 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 1,561,712 $ 6,452,589 Accounts receivable 300,677 - Prepaid expenses 1,981,134 1,433,153 Total current assets 3,843,523 7,885,742 Property and equipment, net 170,537 209,689 Other assets 81,010 1,187,788 Total assets $ 4,095,070 $ 9,283,219 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable $ 3,983,696 $ 2,802,950 Notes payable and accrued interest – related parties 142,292 - Accrued expenses 2,278,308 716,931 Total current liabilities 6,404,296 3,519,881 Commitments (Note 5) Stockholders' equity (deficit): Common stock, $ .001 par value: Authorized shares – 150,000,000 and 600,000,000 at June 30, 2024 and December 31, 2023, respectively Issued and outstanding shares – 4,178,700 and 1,977,152 at June 30, 2024 and December 31, 2023, respectively 4,179 1,977 Additional paid-in capital 112,964,554 110,125,146 Accumulated deficit ( 115,277,959 ) ( 104,363,785 ) Total stockholders' equity (deficit) ( 2,309,226 ) 5,763,338 Total liabilities and stockholders' equity (deficit) $ 4,095,070 $ 9,283,219 See accompanying notes to condensed consolidated financial statements. 1 GEOVAX LABS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Revenue from government contract $ 300,677 $ - $ 300,677 $ - Operating expenses: Research and development 4,276,868 4,719,728 8,702,596 7,538,917 General and administrative 1,086,030 1,459,093 2,543,383 2,910,518 Total operating expenses 5,362,898 6,178,821 11,245,979 10,449,435 Loss from operations ( 5,062,221 ) ( 6,178,821 ) ( 10,945,302 ) ( 10,449,435 ) Other income (expense):
Forward-Looking Statements
Forward-Looking Statements Information included in this Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the " Exchange Act " ). Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We generally use the words " believes, " " expects, " " intends, " " plans, " " anticipates, " " likely, " " will " and similar expressions to identify forward-looking statements. All statements in this Quarterly Report, other than statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, future governmental grants, projected costs, prospects, plans, intentions, expectations and objectives could be forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainti